<DOC>
	<DOC>NCT00519298</DOC>
	<brief_summary>Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.</brief_summary>
	<brief_title>Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Donepezil</mesh_term>
	<criteria>Men or women of nonchildbearing potential aged 18 to 50 years inclusive on study day 1. Body mass index in the range of 18 to 30 kg/m2 and body weight greater than or equal to 50 kg. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital sign measurements, and 12lead electrocardiogram. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, hematologic, neurologic, or psychiatric disease. Clinically significant abnormal standard EEG at screening. Consumption of any caffeinecontaining products or alcoholic beverages within 48 hours before study day 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Alzheimer Disease</keyword>
</DOC>